欢迎访问《现代生物医学进展》编辑部！

目的：探讨重组人血管内皮抑素(恩度)联合FOLFIRI方案治疗结直肠癌肝转移的临床疗效与安全性。方法：选取结直肠癌肝转移患者58 例，随机分为观察组与对照组，每组各29 例。对照组予以FOLFIRI方案，观察组予以恩度联合FOLFIRI方案治疗，均于治疗4 个周期后，观察和比较临床疗效及毒副反应的发生情况，并随访患者的生存情况。结果：观察组与对照组的临床总有效率(RR)分别为44.83%和24.14%，疾病控制率(DCR)分别为89.66%和65.52%，差异具有统计学意义(P<0.05)；毒副反应的发生率分别为44.83%和37.93%，差异无统计学意义(P>0.05)。观察组与对照组无进展生存期(PFS)分别为7.5 个月和4.3 个月，总生存期 (OS)分别为13.2 个月和6.9 个月，差异均具有统计学意义(P<0.05)。结论：重组人血管内皮抑素联合FOLFIRI方案治疗结直肠癌肝转移的临床疗效较单用FOLFIRI方案更好，但并未显著增加毒副反应，安全性较好，值得临床推广应用。

英文摘要:

Objective:To explore the clinical efficacy and safety of recombinant human endostatin (endostar) combined with FOLFIRI regimen in the treatment of colorectal cancer with hepatic metastasis.Methods:58 cases of colorectal cancer with hepatic metastasis were selected and randomly divided into the observation group and control group, 29 patients per group. Patients in the control group were treated by FOLFIRI regimen, while patients in the observation group were treated with endostar and FOLFIRI regimen. The clinical effect and adverse reaction were observed and compared after 4 periods, and the survival were followed-up.Results:The clinical total effective rate (RR) in observation group and control group were 44.83% and 24.14%, disease control rate (DCR) were 89.66% and 65.52%, and there were statistical difference between two groups(P＜0.05). The incidence rates of adverse reactions in observation group and control group were 44.83%and 37.93%, and there was no statistical difference between two groups (P＞0.05). The progression free survival (PFS) in observation group and control group were 7.5 months and 4.3 months, and overall survival (OS) were 13.2 months and 6.9 months, and there were statistical difference between two groups (P＜0.05).Conclusion:The clinical efficacy of recombinant human endostatin (endostar) combined with FOLFIRI regimen in the treatment of colorectal cancer with hepatic metastasis was much more effective than FOLFIRI regimen alone, which had good safety and was worth being popularized in clinic.

查看全文查看/发表评论下载PDF阅读器

关闭